Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability
- PMID: 38768766
- DOI: 10.1016/j.ejpb.2024.114333
Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability
Abstract
Developing co-amorphous systems is an attractive strategy to improve the dissolution rate of poorly water-soluble drugs. Various co-formers have been investigated. However, previous studies revealed that it is a challenge to develop satisfied acidic co-formers, e.g., acidic amino acids showed much poorer co-former properties than neutral and basic amino acids. Only a few acidic co-formers have been reported, such as aspartic acid, glutamic acid, and some other organic acids. Thus, this study aims to explore the possibility of adenosine monophosphate and adenosine diphosphate used as acidic co-formers. Mebendazole, celecoxib and tadalafil were used as the model drugs. The drug-co-former co-amorphous systems were prepared via ball milling and confirmed using XRPD. The dissolution study suggested that the solubility and dissolution rate of the drug-co-formers systems were increased significantly compared to the corresponding crystalline and amorphous drugs. The stability study revealed that using the two nucleotides as co-formers enhanced the physical stability of pure amorphous drugs. Molecular interactions were observed in MEB-co-former and TAD-co-former systems and positively affected the pharmaceutical performance of the investigated co-amorphous systems. In conclusion, the two nucleotides could be promising potential acidic co-formers for co-amorphous systems.
Keywords: Co-amorphous systems; Dissolution rate; Nucleotides; Physical stability; Poorly water-soluble drugs.
Copyright © 2024 Elsevier B.V. All rights reserved.
Similar articles
-
Dipeptides as co-formers in co-amorphous systems.Eur J Pharm Biopharm. 2019 Jan;134:68-76. doi: 10.1016/j.ejpb.2018.11.016. Epub 2018 Nov 20. Eur J Pharm Biopharm. 2019. PMID: 30468836
-
Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.Eur J Pharm Sci. 2021 Jan 1;156:105582. doi: 10.1016/j.ejps.2020.105582. Epub 2020 Oct 8. Eur J Pharm Sci. 2021. PMID: 33039568
-
Aspartame as a co-former in co-amorphous systems.Int J Pharm. 2018 Oct 5;549(1-2):380-387. doi: 10.1016/j.ijpharm.2018.07.063. Epub 2018 Jul 31. Int J Pharm. 2018. PMID: 30075253
-
Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.Expert Opin Drug Deliv. 2020 Oct;17(10):1411-1435. doi: 10.1080/17425247.2020.1796631. Epub 2020 Sep 17. Expert Opin Drug Deliv. 2020. PMID: 32683996 Review.
-
Drug-drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs.Drug Discov Today. 2024 Feb;29(2):103883. doi: 10.1016/j.drudis.2024.103883. Epub 2024 Jan 14. Drug Discov Today. 2024. PMID: 38219970 Review.
Cited by
-
Cutting-Edge Approaches in the Co-Amorphization Process.Pharmaceutics. 2025 Jun 29;17(7):850. doi: 10.3390/pharmaceutics17070850. Pharmaceutics. 2025. PMID: 40733059 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources